BIOMAT Database Logo BIOMAT Database Logo

HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway. 2023

Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Lung adenocarcinoma is one of the most common tumors, and cisplatin is frequently used in treating lung adenocarcinoma patients. This study aimed to look into the roles and mechanisms of HNF4G in cisplatin resistance of lung adenocarcinoma. Cisplatin resistance and gene expression data of 542 cell lines from the CTRP and CCLE databases were analyzed. HNF4G expression was detected in the lung adenocarcinoma cell lines after treatment with various concentrations of cisplatin. Cisplatin sensitivity curves were detected in cells that overexpressed or knocked down HNF4G. The ChIP-Seq data were then analyzed to identify the targets of HNF4G involved in cisplatin resistance. Expression and phosphorylation of the MAPK6/Akt pathway were detected after HNF4G was overexpressed or knocked down. Finally, ChIP-qPCR and dual-luciferase assays were used to investigate the regulation of HNF4G on MAPK6. In cell lines, high expression of HNF4G was significantly positively correlated with cisplatin resistance, and lung adenocarcinoma patients who had high HNF4G expression had a poor prognosis. Cisplatin treatment increased HNF4G expression, and overexpression of HNF4G significantly increased the resistance to cisplatin in A549 and HCC827 cells, whereas knockdown of HNF4G had the opposite effect. HNF4G overexpression increased MAPK6 expression and activated the MAPK6/Akt pathway, while an Akt inhibitor reduced the effects of HNF4G on cisplatin resistance. HNF4G bound to the MAPK6 promoter region, promoting MAPK6 expression, according to ChIP-qPCR and luciferase assays. By binding to the MAPK6 promoter region, HNF4G promotes MAPK6 expression and subsequent Akt phosphorylation, resulting in resistance to cisplatin in lung adenocarcinoma.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051057 Proto-Oncogene Proteins c-akt Protein-serine-threonine kinases that contain PLECKSTRIN HOMOLOGY DOMAINS and are activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. They play a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells. akt Proto-Oncogene Protein,c-akt Protein,AKT1 Protein Kinase,AKT2 Protein Kinase,AKT3 Protein Kinase,Akt-alpha Protein,Akt-beta Protein,Akt-gamma Protein,Protein Kinase B,Protein Kinase B alpha,Protein Kinase B beta,Protein Kinase B gamma,Protein-Serine-Threonine Kinase (Rac),Proto-Oncogene Protein Akt,Proto-Oncogene Protein RAC,Proto-Oncogene Proteins c-akt1,Proto-Oncogene Proteins c-akt2,Proto-Oncogene Proteins c-akt3,RAC-PK Protein,Rac Protein Kinase,Rac-PK alpha Protein,Rac-PK beta Protein,Related to A and C-Protein,c-akt Proto-Oncogene Protein,Akt alpha Protein,Akt beta Protein,Akt gamma Protein,Akt, Proto-Oncogene Protein,Protein, akt Proto-Oncogene,Protein, c-akt Proto-Oncogene,Proteins c-akt1, Proto-Oncogene,Proteins c-akt2, Proto-Oncogene,Proteins c-akt3, Proto-Oncogene,Proto Oncogene Protein Akt,Proto Oncogene Protein RAC,Proto Oncogene Proteins c akt,Proto Oncogene Proteins c akt1,Proto Oncogene Proteins c akt2,Proto Oncogene Proteins c akt3,Proto-Oncogene Protein, akt,Proto-Oncogene Protein, c-akt,RAC PK Protein,RAC, Proto-Oncogene Protein,Rac PK alpha Protein,Rac PK beta Protein,Related to A and C Protein,akt Proto Oncogene Protein,alpha Protein, Rac-PK,c akt Proto Oncogene Protein,c-akt, Proto-Oncogene Proteins,c-akt1, Proto-Oncogene Proteins,c-akt2, Proto-Oncogene Proteins,c-akt3, Proto-Oncogene Proteins
D051557 Hepatocyte Nuclear Factor 4 A subfamily of nuclear receptors that regulate GENETIC TRANSCRIPTION of a diverse group of GENES involved in the synthesis of BLOOD COAGULATION FACTORS; and in GLUCOSE; CHOLESTEROL; and FATTY ACIDS metabolism. HNF4 Transcription Factor,Hepatocyte Nuclear Factor 4-alpha,Hepatocyte Nuclear Factor 4-beta,Hepatocyte Nuclear Factor 4-gamma,Hepatocyte Nuclear Factor-Forkhead Homolog 4,Nuclear Receptor Subfamily 2 Group A, Member 2,Nuclear Receptor Subfamily 2, Group A, Member 1,Hepatocyte Nuclear Factor 4 alpha,Hepatocyte Nuclear Factor 4 beta,Hepatocyte Nuclear Factor 4 gamma,Hepatocyte Nuclear Factor Forkhead Homolog 4,Transcription Factor, HNF4
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
June 2020, Oncology reports,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway.
June 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
March 2019, Oncology reports,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
Resistin increases cisplatin-induced cytotoxicity in lung adenocarcinoma A549 cells via a mitochondria-mediated pathway.
April 2021, Medical oncology (Northwood, London, England),
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
ATAD2 expression increases [18F]Fluorodeoxyglucose uptake value in lung adenocarcinoma via AKT-GLUT1/HK2 pathway.
July 2019, BMB reports,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway.
February 2015, Free radical biology & medicine,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
[CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].
September 2012, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
LIMD1 Increases the Sensitivity of Lung Adenocarcinoma Cells to Cisplatin via the GADD45α/p38 MAPK Signaling Pathway.
January 2020, Frontiers in oncology,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma.
January 2022, Journal of Cancer,
Jiaqi Liang, and Guangyin Zhao, and Yunyi Bian, and Guoshu Bi, and Qihai Sui, and Huan Zhang, and Haochun Shi, and Guangyao Shan, and Yiwei Huang, and Zhencong Chen, and Lin Wang, and Cheng Zhan
Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway.
August 2018, Oncology letters,
Copied contents to your clipboard!